Express News | ChromaDex Announces Ingredient Partnership With Solgar; Solgar Cellular Nutrition Cellular Energy Features NIAGEN To Support NAD+ Levels For Cellular Health
BenzingaApr 30 08:35 ET
Express News | Chromadex Corp - Ingredient Partnership With Solgar, a Nestlé Health Science Brand
ReutersApr 30 08:33 ET
ChromaDex's NIAGEN (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar Cellular Nutrition Cellular Energy Supplement
New ingredient collaboration debuts Solgar's first NAD+ boosting supplement and reinforces NIAGEN as the gold standard in the NAD+ supplement category ChromaDex Corp. (NASDAQ:CDXC), the global authority on
BusinesswireApr 30 08:32 ET
ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe
Tru Niagen is now available at 700 retail locations of The Vitamin Shoppe and Super Supplements and online at vitaminshoppe.comLOS ANGELES--(BUSINESS WIRE)--$CDXC #CellularHealth--ChromaDex Corp. (NAS
BusinesswireApr 25 08:34 ET
Press Release: ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 LOS ANGELES--(BUSINESS WIRE)--April 24, 2024-- ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide
Dow JonesApr 24 08:34 ET
Express News | ChromaDex Announces That Its Flagship Product, Tru Niagen Is Now Available At Sprouts Farmers Market, Marking Its Inaugural Major Grocery Debut
Moomoo 24/7Apr 23 08:36 ET
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen at Sprouts Farmers Market
Tru Niagen expands to health-conscious Sprouts consumers in more than 400 locations across 23 states ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy
BusinesswireApr 23 08:32 ET
ChromaDex Is Maintained at Buy by Roth MKM
ChromaDex Is Maintained at Buy by Roth MKM
Dow JonesApr 9 10:10 ET
Express News | Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $6
Moomoo 24/7Apr 9 09:59 ET
Should You Investigate ChromaDex Corporation (NASDAQ:CDXC) At US$4.32?
While ChromaDex Corporation (NASDAQ:CDXC) might not have the largest market cap around , it saw a significant share price rise of 218% in the past couple of months on the NASDAQCM. The company's
Simply Wall StApr 5 06:35 ET
ChromaDex Announces Tru Niagen Is Now Third-Party Verified Through the Alkemist Assured Transparency Program
All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport) are Alkemist Assured ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and
BusinesswireMar 26 08:32 ET
12 Health Care Stocks Moving In Monday's Intraday Session
GainersFresh2 Group (NASDAQ:FRES) shares rose 41.7% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $15.7 million. Akso Health Group (NASDAQ:AHG) stock mov
BenzingaMar 18 13:31 ET
ChromaDex Corporation's (NASDAQ:CDXC) Shares Leap 47% Yet They're Still Not Telling The Full Story
Despite an already strong run, ChromaDex Corporation (NASDAQ:CDXC) shares have been powering on, with a gain of 47% in the last thirty days.
Simply Wall StMar 16 10:31 ET
ChromaDex Is Maintained at Buy by HC Wainwright & Co.
ChromaDex Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 11 07:33 ET
Express News | HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $6
Moomoo 24/7Mar 11 07:23 ET
ChromaDex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/11/2024 246.82% HC Wainwright & Co. $5 → $6 Maintains Buy 08/10/2023 189.02% HC Wainwright & Co. → $5 R
BenzingaMar 11 07:21 ET
ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results With Positive Adjusted EBITDA
Yahoo FinanceMar 7 13:59 ET
Q4 2023 Chromadex Corp Earnings Call
Yahoo FinanceMar 7 06:27 ET
Earnings Call Summary | ChromaDex(CDXC.US) Q4 2023 Earnings Conference
The following is a summary of the ChromaDex Corporation (CDXC) Q4 2023 Earnings Call Transcript:Financial Performance:ChromaDex reported Q4 revenue of $21.2 million, a positive adjusted EBITDA of $1.2
moomoo AIMar 6 23:39 ET · Conference Call
Express News | ChromaDex Expects Trajectory Of 2024 Revenue Growth To Continue, Projecting Higher Rate Of Revenue Growth Than Prior Year Growth Of 16%
Moomoo 24/7Mar 6 16:23 ET
No Data
No Data